Lab-grown tracheas are now being implanted into patients, with other hollow organs soon to follow. Hearts, kidneys, livers, etc. are the longer-term goal, of course, and an increasingly realistic one. The opening of Ariel Schwartz Fast Company blog post on the topic:

“In 2011, an Eritrean man named Andemariam Teklesenbet Beyen was dying from tracheal cancer. The tumor in his windpipe was, the doctors explained, too big to remove. There was no time to wait for a donor organ to show up.

In years past, this might have been the end of the line for Beyen. Instead, he received a healthy new windpipe, made from his own cells. Beyen was the first of eight patients to receive a trachea grown on synthetic scaffolding in a laboratory. And so far, just two have died, from causes unrelated to their transplants. Harvard Apparatus Regenerative Technology, the regenerative medicine company behind many of the innovations used in the trachea transplants, believes we’re only seeing the beginning of the lab-grown organ industry.

‘We make regenerated organs for transplant. I know it sounds all kinds of science-fictiony. I think we’ve proven with the trachea that this approach works,’ says CEO David Green.

HART, a spinoff from Harvard Bioscience, sees a booming business in lab-grown organs. Green estimates that there is a $600 million per year revenue opportunity for trachea transplants alone. ‘The major technological hurdles have been overcome. Now the main issues are regulatory,’ he says.”